NEWS HIGHLIGHTSMedia Articles Related to Zonegran (Zonisamide)
Pediatric Fever-Induced Seizures Reduced By Common Drug
Source: Epilepsy News From Medical News Today [2013.06.14]
Fever-induced childhood seizures, known as febrile seizures, can be terrifying for parents to witness. The full-body convulsions, which mostly affect children six months to five years old, can last from mere seconds up to more than 40 minutes...
Implanted Device Predicts Epilepsy Seizures In Humans
Source: Epilepsy News From Medical News Today [2013.05.02]
For the first time, a small device implanted in the brain has accurately predicted the onset of seizures in some adults who have epilepsy that doesn't respond to drugs, according to a small proof-of-concept study published Online First in The Lancet Neurology...
Implanted Device May Predict Epilepsy Seizures, Study Suggests
Source: MedicineNet Seizure Specialty [2013.05.02]
Title: Implanted Device May Predict Epilepsy Seizures, Study Suggests
Category: Health News
Created: 5/2/2013 10:35:00 AM
Last Editorial Review: 5/2/2013 12:00:00 AM
Experimental Treatment For Rare Pediatric 'Pretzel Syndrome' Halts Intractable Seizures
Source: Epilepsy News From Medical News Today [2013.04.26]
With a better understanding of underlying mechanisms that cause a rare neurodevelopmental disorder in the Old Order Mennonite population, referred to as Pretzel syndrome, a new study reports that five children were successfully treated with a drug that modifies the disease process, minimizing seizures and improving receptive language...
TBI Increases Odds For Depression, Behavior Impulsivity, PTSD In Patients With Nonepileptic Seizures
Source: Epilepsy News From Medical News Today [2013.04.10]
A new study by a Rhode Island Hospital researcher has found that traumatic brain injury (TBI) can significantly increase the odds of having major depression, personality impulsivity and post-traumatic stress disorder (PTSD) in patients with psychogenic nonepileptic seizures (PNES). The paper, by W. Curt LaFrance Jr., M.D., M.P.H...
Published Studies Related to Zonegran (Zonisamide)
Zonisamide: its pharmacology, efficacy and safety in clinical trials. [2012]
Zonisamide is a benzisoxazole derivative, chemically unrelated to other
antiepileptic drugs, that appears to have multiple mechanisms of action,
including inhibition of Na(+) channels and reduction of T-type Ca(2+) currents. It is currently licensed in Europe and the USA for adjunctive treatment of
partial seizures in adults, and in Europe as monotherapy for treatment of partial
seizures in adults with newly diagnosed epilepsy...
Assessment of treatment algorithms including amantadine, metformin, and zonisamide for the prevention of weight gain with olanzapine: a randomized controlled open-label study. [2011.05.17]
CONCLUSIONS: Pooled treatment algorithm results were not significantly different from olanzapine monotherapy in mitigating weight gain. However, participants who received treatment with metformin with possible progression to amantadine and then zonisamide had significantly less mean weight gain than participants treated with olanzapine alone. Progression of some participants through the algorithm indicated that a single therapy solution may not be adequate for every patient. Patients treated with olanzapine should receive regular weight monitoring. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00401973. (c) Copyright 2011 Physicians Postgraduate Press, Inc.
Efficacy and safety of adjunctive zonisamide in adult patients with refractory partial-onset epilepsy: a randomized, double-blind, placebo-controlled trial. [2011]
BACKGROUND AND OBJECTIVE: Clinical studies have reported that zonisamide is effective for a wide range of seizure types, including refractory partial-onset seizures. However, there have been no reported studies of the efficacy of zonisamide in the Chinese population to date. The aim of the present study was to evaluate the efficacy and safety of zonisamide in the treatment of adult Chinese patients with refractory partial-onset epilepsy... CONCLUSION: Zonisamide 300-400 mg/day is effective and well tolerated as an adjunctive drug in adult Chinese patients with refractory partial-onset epilepsy.
Zonisamide versus topiramate in migraine prophylaxis: a double-blind randomized
clinical trial. [2011]
it could be used as an alternative for noncompliant patients to topiramate... CONCLUSION: Our results indicated that zonisamide is as effective as topiramate
Zonisamide for bipolar disorder, mania or mixed states: a randomized, double
blind, placebo-controlled adjunctive trial. [2011]
CONCLUSIONS: In contrast to previous studies that suggested efficacy of
Clinical Trials Related to Zonegran (Zonisamide)
Zonegran for the Treatment of Weight Gain Associated With Psychotropic Medication Use: A Placebo-Controlled Trial [Active, not recruiting]
The primary objective of this study is to compare the efficacy of zonisamide (Zonegran; 100mg
- 400mg/day) and placebo as an adjunctive agent on lowering weight in subjects who have a
body mass index (BMI) of >25 and are on a psychotropic medication with a known side effect of
weight gain.
Evaluation of the Efficacy and Safety of Adjunctive Zonisamide vs Replacement With Zonisamide of the Last Added Antiepileptic Drug [Recruiting]
An open-label, randomized, multi-centre, superiority study to assess that, in patients who
respond to zonisamide added as third drug after failure of a two-drug combination therapy,
the triple therapy is superior to the conversion to a double therapy including zonisamide.
Fed Study of Zonisamide Capsules 100 mg and Zonegran® Capsules 100 mg [Completed]
The objective of this study was to investigate the bioequivalence of Mylan's zonisamide, 100
mg capsules to Elan's Zonegran® 100 mg capsules following a single, oral 100 mg (1 x 100 mg)
dose administered under fed conditions.
Fasting Study of Zonisamide Capsules 100 mg and Zonegran® Capsules 100 mg [Completed]
The objective of this study was to investigate the bioequivalence of Mylan's zonisamide, 100
mg capsules to Elan's Zonegran® 100 mg capsules following a single, oral 100 mg (1 x 100 mg)
dose administered under fasting conditions.
Zonisamide for Heavy Drinkers With Bipolar Disorder [Recruiting]
This is a randomized, double blind, placebo controlled trial of the medication zonisamide
for the purpose of reducing heavy drinking and drinking, as well as reducing mood symptoms,
in bipolar subjects that drink excessively and heavily.
Hypotheses: (Primary aims); Add-on zonisamide compared to placebo will result in:
1. significant reduction in heavy drinking days, drinks per week and per drinking day, and
significantly greater increase in abstinent days, ii) greater rates of abstinence and
abstinence to heavy drinking, greater reduction in biomarkers of heavy alcohol use such
as gamma-glutamyl transferase (GGT), and greater reduction in alcohol urge or
"craving",
2. Significant reduction in prevalent mood symptoms on the BRMS and BRMeS, CARS, HAMD, or
no worsening of euthymic mood, and significant improvement on the Clinical Global
Impressions Scale-Severity.
3. (Secondary aims) Add-on zonisamide compared to placebo will result in significant
reduction in weight (kilograms) and other secondary weight-related metabolic factors
such as fasting glucose, lipid profile, and blood pressure.
4. (Secondary aims) Add-on zonisamide compared to placebo will result in improved clinical
global impression, overall functioning, quality of life, and reduced medical symptoms.
5.) (Exploratory Aims) To will examine interactions between genotype and medication on
treatment response for allelic variation in genetic loci related to the major
neurotransmitter and neurophysiologic pathways that are relevant to bipolar disorder,
alcoholism, and zonisamide mechanism of action.
Reports of Suspected Zonegran (Zonisamide) Side Effects
Rash (11),
Convulsion (11),
Agitation (8),
Foetal Exposure During Pregnancy (6),
Drug Interaction (6),
Fatigue (6),
Confusional State (5),
Drug Ineffective (5),
Chest Pain (5),
Vomiting (5), more >>
|
